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ABSTRACT 
 
 The objective of this work was to describe bone marrow-derived mesenchymal 
stem cell (MSC) proliferation and characterization after expansion with the common 
intra-articular medications polysulfated glycosaminoglycan, hyaluronic acid, or 
hyaluronic acid with chondroitin sulfates C4 and C6 with N-acetyl-D-glucosamine in 
vitro as an initial screening for combination therapy treatment of degenerative joint 
conditions in the horse.   
 MSCs were isolated from bone marrow, then expanded in basal culture media 
(BCM) or BCM supplemented with a test solution (polysulfated glycosaminoglycan 
(PSGAG); hyaluronic acid (HA); hyaluronic acid, chondroitin sulfates C4 and C6, and 
N-acetyl-D-glucosamine (GAGHA)).  Viability was assessed with colony forming unit 
counts (CFU-F), while proliferation assessments included total cell counts, evaluation of 
growth kinetics with generation tracking intracytoplasmic dye, and culture evaluations of 
confluency and debris.  Characterization by immunophenotyping for surface markers 
CD29, CD44, CD45, and MHCII, evaluation of differentiation ability into adipocytes, 
chondrocytes, and osteoblasts, and morphology scoring in culture was performed. 
Investigation of immunomodulatory activity was assessed by quantification of 
prostaglandin E2 (PGE2) concentration in media supernatants, and senescence was 
evaluated as a follow-up test in cells expanded with PSGAGs or SF treated media with 
β-Galactosidase staining (n = 1). 
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 Results of total cell counts, growth kinetics assessment, and culture evaluations 
for confluency and debris indicated decreased cellular proliferation 72 hours after 
supplementation with PSGAG, GAGHA, and SF.  Viability was decreased in CFU-F 
cultures supplemented with GAGHA and SF, while colonies failed to form in PSGAG 
supplemented cultures.  Viability was increased in CFU-F cultures supplemented with 
HA.  After 120 hours of expansion with test solutions, there were no significant 
differences in trilineage differentiation, immunophenotype, or PGE2 assays. SF cultures 
stained positively for β-Galactosidase activity and osteogenesis after 10 days of 
incubation (n = 1).   
 MSCs expanded with PSGAG, GAGHA, and SF had decreased proliferation and 
viability in vitro, while proliferation of MSCs cultured with HA was not different from 
controls.  MSC viability and proliferation is inhibited in the presence of PSGAG in vitro.  
In contrast, viability of MSCs may be improved in the presence of HA, and proliferation 
is not adversely affected.  The results of this study warrant in vivo evaluation. 
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NOMENCLATURE 
 
OA Osteoarthritis 
SJ Synovial Joint 
SF Synovial Fluid 
ECM Extracellular Matrix 
HA Hyaluronic Acid 
PSGAG Polysulfated Glycosaminoglycans 
PGE2 Prostaglandin E2 
NSAID Non-Steroidal Anti-Inflammatory Drug 
DMOAD Disease-Modifying Osteoarthritis Drug 
AAEP American Association of Equine Practitioners 
GAGHA Polyglycan (hyaluronic acid + chondroitin sulfates C4 & C6 +  
 N-acetyl-D-glucosamine) 
MSC Mesenchymal Stem Cell or Multipotent Stromal Cell 
BCM Basal Culture Media 
CTV CellTrace
®
 Violet 
CFU-F Colony Forming Unit – Fibroblastic 
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CD90 Thy-1 
MHCII Major Histocompatibility Complex Class II 
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1. INTRODUCTION  
 
 Equine athletes endure substantial stress to joints during training and 
competition.  Stress resulting in acute or chronic inflammation can lead to joint disease 
or osteoarthritis (OA), which causes approximately 60% of lameness in horses and often 
removes athletes from competition
1,2
.  Joint disease and OA affect synovial joints (SJ) in 
the appendicular skeleton in joints such as the carpal, metacarpophalangeal, proximal 
interphalangeal, distal interphalangeal, medial and lateral femorotibial and 
femoropatellar, and tarsal joints
2,3
.   
 
1.1 Joint Anatomy  
 SJs are connections between bones, comprised of articular cartilage with 
underlying subchondral bone, surrounded by a joint capsule, lined by synovial 
membrane, and lubricated by synovial fluid (SF)
4
.  Articular cartilage is comprised of 
hyaline cartilage extracellular matrix (ECM), which absorbs shock and provides smooth 
surfaces for gliding of bones
4
.   
 Articular cartilage matrix is supported by SF, an ultrafiltrate of the blood, as it is 
an avascular, multi-layered tissue with decreasing cell density and increasing matrix 
density towards the articular surface
4
.  The dynamic composition of chondral ECM 
allows its unique function.  Collagen, a tripolypeptide arranged in a lattice network, 
resists pulling forces and anchors cells, while lamina adds integrity to the collagen 
network of the basement membrane
4
.  Fibronectin is a repeated protein with specific 
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interaction regions such as the RGD loop in the cell binding domain, which binds cells 
via integrin molecules
5
.  Proteoglycans play an essential role in articular cartilage 
function, with aggregates providing gel-like support and integrity to the ECM
4
.  
Hyaluronic acid (HA), a high molecular weight glycosaminoglycan (> 1 x 10
6
 Da) 
composed of repeating disaccharide units of D-glucuronic acid and N-acetyl-D-
glucosamine, is naturally secreted into joints by mesenchyme to provide lubrication and 
shock absorption through viscoelasticity, and is a major component of chondrocyte-
produced ECM
4,6-10
.  Naturally occurring polysulfated glycosaminoglycans (PSGAG) 
such as keratin sulfates and chondroitin sulfates are held together by a core protein 
linked to HA to form proteoglycan aggregates in the ECM
4
.  Water helps to cushion 
mechanical loading of the joint, attracted into the cartilage by the strong negative charge 
of sulfate residues in aggrecan monomers
4
.  These elements together allow articular 
cartilage to withstand the simultaneous forces of loading, shear stress, and compression 
during locomotion.   
 
1.2 Joint Pathology   
 Early stage joint disease and OA are often overlooked, as initial damage of 
aneural articular cartilage may not result in immediate pain and lameness
11
.  HA and 
PSGAG in articular cartilage become depleted, and subchondral bone can be exposed to 
the articular surface
1
.  Hallmarks of OA are osteophyte formation at the joint capsule 
margin, subchondral bone lysis, and synovial fluid of increased total protein, white blood 
cell, glycosaminoglycan, and PGE2 content
12
.  The body responds to damage within the 
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joint cavity with production of inflammatory factors such as prostaglandin E2 (PGE2), 
interleuken-8 ( IL-8), IL-1β, tumor necrosis factor-α (TNF-α), and matrix 
metalloproteinases (MMP) to initiate inflammation
13,14
.  Osteoclast recruitment and 
activity is increased in the presence of PGE2, resulting in increased bone resorption
13
.  
MMP-1 and MMP-13 are secreted by synovial cells and chondrocytes, respectively, and 
contribute to aggrecan and collagen degradation, resulting in lesions of the meniscus and 
other cartilaginous structures
15
.  These degenerative processes trigger additional 
inflammatory cascades, resulting in an influx of pro-inflammatory cytokines, joint 
effusion, and increased pain
13
. SF loses viscosity under inflammatory conditions, as high 
molecular weight HA degrades into smaller fragments, which accumulate and have 
opposite effects within the joint than the larger molecular form
9,10
.  In all, severe injury 
or degeneration of SJ components triggers an amplifying cascade, resulting in complete 
loss of joint function if untreated. 
 Due to the avascular nature and limited cell population of articular cartilage, 
repair is a slow and rarely complete process
16
.  Therefore, degenerative processes driven 
by chronic inflammation present a greater challenge to healing and regeneration than 
acute injuries of cartilaginous structures.  There are several treatment options to 
minimize inflammation and pain in both chronic and acute cases, as well as address the 
disease process. 
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1.3   Conventional Treatment Options 
 Though the disease itself is not reversible, treatments decreasing inflammation 
and pain can lessen the impact of symptoms and hinder disease progression.  The least 
invasive options are external or topical treatments such as extracorporeal shockwave 
therapy or topical non-steroidal anti-inflammatory drugs (NSAIDs)
2,17
.  Both of these 
options are pain modulating, but offer no disease modification
2
.  Systemic treatment 
with NSAIDs or selective NSAIDs can provide long-term benefits and slow progression 
of OA in cases of chronic inflammation by inhibiting cyclooxygenase enzymes
18
.  
Corticosteroids can be injected directly into the joint, and have anti-inflammatory effects 
by inhibiting phospholipase A2 function, thereby inhibiting liberation of arachidonic acid 
from the plasma membrane of cells and inhibiting production of prostaglandins, 
thromboxanes, and leukotrienes
2
.  However, chronic NSAID intra-articular 
administration demonstrated fibrosis of cartilaginous structures in the rat model, and 
short-term exposure of equine chondrocytes to corticosteroid resulted in decreased 
proteoglycan production in another study
19,20
.  A human study of intra-articular 
corticosteroid administration for treatment of OA indicated a risk of increased cartilage 
loss compared to untreated joints, while an equine study revealed increased aggrecan 
turnover, cleavage of collagen I and II, and type II collagen synthesis following repeated 
intra-articular administration of corticosteroid in treated and contralateral control 
joints
21,22
.  These findings indicate local and systemic adverse effects of corticosteroids 
on articular cartilage.  Therefore, intra-articular treatment with these medications should 
be used with caution in cases with cartilage damage.   
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 Alternatively, potentially disease modifying osteoarthritis drugs (DMOAD) such 
as Adequan, HA, and Polyglycan have become popular treatments to slow disease 
progression.  In a 2009 survey, Ferris et al. reported Adequan to be the most frequently 
used DMOAD among American Association of Equine Practitioners (AAEP) member 
respondents (62.8%)
23
.  Among those respondents, Adequan was used as a prophylactic 
treatment, in chronic cases, and post-surgically, administered intramuscularly (IM) the 
majority of the time (84.1%)
23
.  HA in the form of Legend (10 mg/mL) was used second 
most frequently (57.4%), followed by Hylartin-V (10 mg/mL), and Hyvisc (11 mg/mL) 
for various applications
23
.  Finally, 18% of respondents reported using Polyglycan 
(GAGHA) intra-articularly for OA treatment, though it is not labeled for intra-articular 
injection in the United States, but as a post-surgical intra-articular lavage
23
.  Hyaluronan 
products were most commonly used for combination with corticosteroids (59.4%), 
followed by the antibiotic amikacin sulfate (56.9%) and Adequan (4.7%)
23
. 
 HA occurs naturally within the joint at a high average molecular weight in the 
homeostatic state
2,14
.  This component of cartilage and synovial fluid can complex with 
the glycoprotein lubricin to form boundary lubricant complexes which reduce friction 
during movement, and is present in synovial fluid, providing its viscoelastic property
14
.  
In the disease state, HA in the joint environment becomes depleted, therefore intra-
articular supplementation can be beneficial
2
.  Supplementation of high molecular weight 
HA stimulates endogenous HA production by synoviocytes, provides anti-inflammatory 
action by inhibiting macrophages and lymphocytes, reduces prostaglandins and catabolic 
enzymes, improves SF viscosity, and reduces pain
2
.  Anti-inflammatory effects of HA 
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are believed to be CD44 membrane receptor mediated, and occur through suppression of 
LPS-induced COX-2 production of PGE2
14
.  Downstream effects of CD44 mediated 
anti-inflammatory action include downregulation of IL-8, TNF-α, IL-1β and therefore 
the ADAMTS protease enzyme family, resulting in decreased aggrecan degradation
14
.  
Anti-nociceptive actions after HA administration are also documented
14
.   
 PSGAG supplementation provides chondroprotection and some anti-
inflammatory action by inhibiting degradation signaled by inflammatory cytokines and 
prostaglandins
2
.  Chondroprotection, or the protection of tissues from catabolic activity 
within the inflamed joint, has been demonstrated in several animal models, including the 
rabbit, dog, and horse, by means of physical, histological, and radiographic 
assessments
24
.  Glade et al. revealed a stimulating effect of PSGAG on chondrocyte 
cultures, which had increased hyaline ECM production when cultured with PSGAG
25
.  
Counterintuitively, proliferation of chondrocytes in the presence of PSGAG was 
inhibited in this study
25
.  A study of PSGAG and HA in treatment of an induced OA 
model revealed that PSGAG was superior to HA in reducing synovial effusion, synovial 
membrane vascularity, and fibrosis of the subintima
26
.    This medication is helpful for 
slowing disease progression, but does not reverse the disease process. 
 GAGHA also provides some disease modification according to a study 
conducted in 2013, which demonstrated modest improvements in lameness, cartilage 
erosion, and bone proliferation, however, synovial fluid PGE2 was not reduced
27
.  In the 
same study, horses treated with HA also saw no reduction in PGE2, but gross articular 
cartilage fibrillation was reduced.  The persistence of PGE2 suggests that alternate means 
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besides PGE2 reduction produced the clinical sign improvements observed with 
GAGHA and HA treatment
26,27
.  This is in contrast to treatment with corticosteroids or 
IL-1 antagonist applied via gene therapy, which reduced synovial fluid prostaglandin 
significantly when studied in the same model of OA
28,29
.  The 2013 study indicates 
GAGHA or HA as possible alternatives for cases nonresponsive to corticosteroids or IL-
1 antagonists, though reduction in lameness with corticosteroids (56% reduction) or IL-1 
antagonists (63% reduction) was greater than that achieved with GAGHA (16% 
reduction)
27
.  
 
1.4   Mesenchymal Stem Cells used in Regenerative Medicine  
 Regenerative medicine has many applications for both human and animal 
patients, including treatment of diseases afflicting the musculoskeletal, cardiovascular, 
and nervous systems
30,31
.  The field of regenerative medicine studies the body’s many 
methods of healing to manufacture artificial alternatives for replacing or supplementing 
the body with cells, tissues, and organs for the treatment of various diseases
32
.   
 The equine model is recognized by the US Food and Drug Administration and 
the European Medicines Agency as an ideal translational model for musculoskeletal 
disease in humans
31,33,34
.  The horse provides the advantage of a more comparative 
model than that in mice or rabbits, as joint anatomy, load proportion, and injury and 
disease state are more similar to that occurring in humans
31,35,36
.  Further, cell-based 
therapies applicable to human joint pathologies are most appropriately demonstrated in 
the equine model
37
. 
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 Intra-articular injection of autologous mesenchymal stem cells (MSCs) is a 
viable treatment option for joint disease and OA patients
38
.  MSCs have low major 
histocompatibility complex (MHC) expression, therefore have a low propensity to cause 
an immune response post-injection, and have the capacity to respond to their 
environment
39,40
.  MSCs are capable of changing to a pro-inflammatory or anti-
inflammatory phenotype depending on local signals
40
.  They secrete a range of soluble 
factors, influencing endogenous cell proliferation and function, angiogenesis, tissue 
repair, and inflammation
41
.  The exact mechanisms of action and possible extent of MSC 
therapy are yet to be discovered, and are currently being investigated. 
 Intra-articular MSC administration is currently used to provide trophic, 
immunomodulatory and anti-inflammatory benefits to patients with joint disease
42
.  
Trophic effects are believed to be due to the release of various paracrine trophic factors, 
growth factors, and chemokines, such as vascular endothelial growth factor (VEGF), 
platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), stem cell factor 
(SCF), stromal cell-derived factor-1 (SDF-1), and others
43
.  These factors promote 
wound healing, tissue repair, and angiogenesis in damaged tissues by signaling 
endogenous cells such as chondrocytes, synoviocytes, and endothelial cells when 
injected into the injured or diseased joint
43
.  MSCs are similarly capable of modulating 
immune cells and inflammation
43
.  Studies have shown that macrophages can be induced 
by MSCs to secrete IL-10, or human cytokine synthesis inhibitory factor, and that MSC 
secretion of soluble factors such as transforming growth factor-β (TGF-β) and PGE2 can 
suppress natural killer (NK) cell, T cell, and B cell activity and proliferation
43
.  
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Barrachina et al. demonstrated that MSCs primed by an inflammatory environment 
containing pro-inflammatory factors TNFα and interferon-γ (IFNγ) respond, at least in 
part, by upregulating immunoregulatory-related genes such as vascular adhesion 
molecule 1 (VCAM-1), indoleamine 2,3-dioxygenase (IDO), inducible nitric oxide 
synthase (iNOS), IL-6, and cyclooxygenase-2 (COX-2)
42
.  Production of soluble factors 
such as these alters the actions of surrounding cells drives the environment towards a 
homeostatic state of balanced catabolic and anabolic processes
40
.  Berebichez-Fridman et 
al. report that studies of intra-articular injection of MSCs in pre-clinical osteoarthritis 
models have demonstrated results including clinical improvement, evidence of 
chondroprotection, inhibition of osteoarthritis progression, and decreased PGE2 in 
synovial fluid
12
.  Specifically, a study in a caprine model of posttraumatic osteoarthritis 
demonstrated reduced articular cartilage degeneration and osteophyte remodeling six 
weeks after MSC injection
44
.  They proposed that injected MSCs induced regeneration 
of meniscal tissue by endogenous cells via paracrine signaling, as implanted cells were 
present on the surface of regenerated tissue, but not within
44
.  These findings and others 
demonstrate the prospect of MSCs as a biological therapy to promote tissue regeneration 
and moderate inflammation in the injured or diseased joint environment through 
paracrine activity
45,46
.   
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1.5  Mesenchymal Stem Cell Identity 
 In general, stem cells are defined by the two unique features of self-renewal and 
potency.  Self-renewing stem cells are capable of multiple divisions, which produce 
identical daughter cells
47
. This type of division allows replication and propagation.  
Potency refers to the stem cells’ capability to remain undifferentiated until receipt of 
signals from their niche or culture environment
47
.  Totipotent stem cells, the result of 
oocyte fertilization, are capable of differentiating into all embryonic and placental cell 
types
47
.  These cells have the greatest capacity to differentiate and therefore the greatest 
potency of all stem cell types.  Pluripotent stem cells derive from totipotent cells and 
develop into the three germ layers forming the embryo
47
.  Multipotent stem cells have 
the capacity to differentiate into a close family of cell types, while unipotent stem cells 
can only produce one type of cell, their own, and are distinguished as stem cells in a 
specific tissue due to their self-renewing capability through asymmetrical division
47
.  
Therefore, adult stem cells are either multipotent or unipotent.  MSCs have the greatest 
potency of adult tissue-derived stem cells, first described as osteogenic precursors by the 
work of Friedenstein et al. in 1966, and first described as having multi-lineage potential 
by Pittenger et al. in 1999 due to their ability to differentiate into several different cell 
types of the mesenchymal lineage
48
.  MSCs can be found in all tissues of the body, and 
can be harvested from peripheral blood, synovial fluid, adipose tissue, and bone 
marrow
49
.  After harvest from adult tissues, MSCs can be maintained or manipulated in 
culture.   
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 Bone marrow houses a heterogeneous population of cells, including MSCs, 
hematopoietic stem cells (HSCs), and adipocytes, supplying the body with a continuous 
supply of hematopoietic and mesenchymal lineage precursors
47,50,51
.  MSCs secrete fluid 
factors into the perivascular niche to support HSC maintenance along with adhesive 
interactions
52,53
.  The stem cell niche also provides MSCs with signals and growth 
factors necessary to prevent differentiation while allowing asymmetrical division, 
delivering cells to the body as needed without depleting the supply pool
54
.  MSCs are 
isolated in culture from bone marrow harvested from sternal bodies or the ilium in 
horses
55
.   
 Equine MSCs are characterized in culture by plastic adherence, the presence or 
absence of specific cell surface markers, and the capability to differentiate into lineages 
of the mesenchyme, such as osteoblasts, chondrocytes, and adipocytes, in vitro
56,57
.  
They are morphologically spindle-shaped and fibroblast-like, and proliferate in 
monolayer in culture
57
.  The criteria of plastic adherence and capacity for trilineage 
differentiation are uniform across species, however, the requirements of the 
immunophenotypic profile of equine MSCs have not been defined, as equine-specific 
antibodies are not widely available
30,31,57,58
.   
 Immunophenotyping of cell samples ensures the presence of MSCs and the 
absence of HSCs or any other cell population due to differences in antigen 
presentation
57
.  According to guidelines set forth by the International Society for Cellular 
Therapy (ISCT), human MSCs express CD105, CD73, and CD90, and lack CD45, 
CD34, CD14, CD19, and HLA-DR expression
56,58
.  No specific panel has been 
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assembled for equine MSC identification, as commercially available specie-specific 
antibodies are not widely available
57
.  According to others, equine MSCs should express 
cellular protein markers CD29, CD44, and CD90, and lack expression of CD45 and 
MHCII
57,59
.  Other markers have been added or substituted in other studies to verify 
isolation and specie-specific identity in culture
31,57
.  Integrin β-1, or CD29, is a surface 
adhesion and recognition molecule involved in multiple processes including the immune 
response and tissue repair
60
.  This surface molecule is common in fibroblast-like cells, 
and highly expressed in MSCs
60
.  CD44 is involved in cell adhesion, migration, 
interaction, and proliferation, is a receptor for hyaluronic acid (HA), and can promote T-
lymphocyte activation
31,61,62
.  CD90, also known as Thy-1, is a regulator of cell-to-cell 
and cell-to-matrix communications during migration and fibrosis and can also promote 
T-lymphocyte activation
63
.  CD45 is a hematopoietic (B-cell) marker, while major 
histocompatibility complex class II, or MHCII, is found on antigen-presenting cells 
which initiate immune reactions
64,65
.  Low expression of MHCII is thought to provide 
MSCs with immunoprivilege, a key in their immunomodulatory actions and use for 
injection
65,66
.   
 Multiple studies exist demonstrating that MSCs cryopreserved in liquid nitrogen 
show no change in morphology, proliferation, cell surface marker profile, or trilineage 
differentiation potential
67-69
.  The use of cryopreservation facilitates clinical and research 
applications of MSCs. 
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2. PROBLEM
2.1   Combination Therapy 
Intra-articular medications and regenerative medicine may be combined as an 
effective treatment approach for OA patients, resulting in enhanced disease 
modification, allowing the animal to return to training or competition faster.  However, 
combination of MSCs with the intra-articular medications Adequan and Polyglycan has 
not been studied previously to determine their effects on MSC viability, proliferation, 
characterization, and immunomodulation.  
2.2   Preliminary Data 
 A pilot study was conducted to evaluate effects PSGAG, HA, and GAGHA on
  MSC proliferation and characterization in vitro.  It was hypothesized that MSC 
proliferation and characterization would not change after exposure to these test 
solutions.  Cryopreserved MSCs from 6 horses of various age, breed, and passage were 
thawed as previously described, stained with CellTrace™ Violeta cytoplasmic dye,
aliquoted, resuspended in 1mL per test solution (Dulbecco’s phosphate buffered saline 
(DPBS, control), Adequan
b
 (PSGAG; 100 mg/mL polysulfated glycosaminoglycan),
HA
c
 (11 mg/mL hyaluronic acid sodium salt), Polyglycan
d
 (GAGHA; 5mg/mL
hyaluronic acid sodium salt, 100mg/mL sodium chondroitin sulfate, 100mg/mL N-
acetyl-D-glucosamine), or pooled SF) for 5 minutes, then plated in the resuspension 
medias to tissue culture flasks (10,000 cells/cm
2
) and 10cm culture dishes (1000
a
 ThermoFisher Scientific, Rochester, NY, USA 
b
 Lutipold Pharmaceuticals, Shirley, NY, USA 
c
 Boehringer Ingelheim Vetmedica, Inc., St. Joseph, MO, USA 
d
 ArthroDynamic Technologies, Lexington, KY, USA 
14
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cells/dish) with basal culture media (BCM) for the colony forming unit-fibroblastic 
(CFU-F) assay
69
.  Half of the media was replaced in each flask with BCM after 48 hours 
of incubation.  Cell counts and flow cytometry were performed at 24 and 72 hours to 
assess growth kinetics, and 10cm plates were incubated for 10 days, then stained with 
Crystal Violet to assess viability.  Cell counts, growth kinetics, and CFU-F data were 
analyzed with commercially available software
e
 with the Shapiro-Wilk distribution test 
and repeated measures one-way ANOVA with Dunnett’s multiple comparisons test.  P-
values less than 0.05 were considered significant.  Though no statistically significant 
differences were found between test solution groups and the control within cell count 
and growth kinetics data, MSCs expanded with PSGAG appeared to have decreased cell 
counts and a greater proportion of cells in earlier generations compared to the control 
and other treatments at 72 hours (Figure 1, Figure 2).  The CFU-F assay indicated 
significantly increased viability of MSCs exposed to pooled SF, and decreased viability 
                                                 
e
 GraphPad Software, Inc., La Jolla, CA, USA 
A B 
Figure 2 – Preliminary Data 2 
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when cultured with PSGAGS and HA (Figure 1).  The extremely viscous nature of HA 
could be responsible for the decreased cell counts and CFUs, as much of the cell 
suspension was retained in the pipette tip during seeding of flasks and plates.  Overall, 
preliminary data showed the proliferation of MSCs combined with PSGAG was 
hindered.  Our findings suggested that further investigation was warranted with adjusting 
the experimental techniques to more closely mimic clinical application.  In addition, 
adding assays to evaluate effects on MSC characterization and immunomodulatory 
function would provide greater knowledge of the effects of these medications on MSCs. 
 
 
2.3   Objectives 
 The objective of this study was to determine the effects of the commonly used 
intra-articular drugs PSGAG, GAGHA, high molecular weight HA, and SF on bone 
marrow-derived MSC viability, growth, cell surface marker expression, differentiation 
ability, and PGE2 secretion in vitro.  It was hypothesized that MSCs expanded with 
PSGAG would have decreased viability and proliferation due to the results of the pilot 
study, but that characterization would be unchanged for all test solutions.   
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3. METHODS 
 
3.1    Inclusion Data 
 MSCs were isolated and expanded as previously described
69
.  Donor horse age 
ranged from 4 – 8 years (median, 7).  There were 5 geldings and 1 mare.  Passage 2 – 4 
MSCs were cryopreserved for 2 – 4 years prior to use.  SF was collected post-euthanasia 
from horses euthanized for reasons other than joint disease.  Immediately after 
collection, SF was spun (300 x g, 5 minutes) to remove cells and other debris.  SF was 
frozen for 0 – 39 days prior to use.  No animals were euthanized specifically for the 
purpose of this study, and animal use procedures were approved by the Texas A&M 
University Animal Care and Use Committee (IACUC #20150038). 
 
3.2    Test Solutions 
  Test solutions (Adequan
1
 (PSGAG; 100mg/mL polysulfated 
glycosaminoglycan), hyaluronic acid
f
 (HA; 11mg/mL hyaluronic acid sodium salt from 
streptococcus equi, 1.5-1.8 x 10
6
 Da), Polyglycan
3
 (GAGHA; 5mg/mL hyaluronic acid 
sodium salt, 100mg/mL sodium chondroitin sulfate, 100mg/mL N-acetyl-D-
glucosamine), or SF) were combined with BCM and then sterile filtered to create a 1 
part test solution to 11 parts BCM volumetric ratio for each test solution (Table 1).  The 
original ratio chosen for the project was 5 parts BCM to 1 part test solution to closely 
mimic the average ratio of joint volume to a dose of HA after intra-articular injection 
                                                 
f
 Sigma-Aldrich, St. Louis, MO, USA 
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(Table 2).  The ratio was adjusted to 11:1 for all test solutions for improved practicality, 
which still closely mimicked the ratio of joint volume to a dose of Adequan (10:1; Table 
2).  The 11 mg/mL concentration for HA test solution was chosen to mimic the 
concentration of the commercially available HA product, Hyvisc
g
.  After the first 
passage post-thaw, MSCs were maintained in BCM with test solution for each of the 
assays. 
 
  
                                                 
g
 Boehringer Ingelheim Vetmedica, St. Joseph, MO, USA 
Table 1 – Test Solution Concentrations  
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Table 2 – Approximate joint volumes and intra-articular drug doses.  Joint volumes are in reference to recommended 
volumes of intra-articular anesthetics. 
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3.3   Growth Kinetics Assay 
 MSCs were stained with CellTrace™ Violet Cell Proliferation Kith (CTV) 
according to the manufacturer’s instructions.  CTV-stained cells were plated to tissue 
culture flasks (5700 cells/cm
2
) with BCM or BCM supplemented with test solution and 
incubated for 24 and 72 hours, counted, then cryopreserved.  MSCs were thawed as 
previously described and resuspended in 500μL DPBS69.  Five microliters of 2% PI was 
added to each sample for viability assessment during flow cytometric analysis.  Only 
live cells were analyzed.  Samples were analyzed using a MoFlo Astrios high-speed cell 
sorter and Summit acquisition software
i
.  The flow cytometer used a 405nm laser with a 
488/55 bandpass filter.  The CellTrace™ Violet label excites at 405nm and emits at 
455nm.  The data were modeled using ModFit LT software
j
, and reported as sample 
percentages in each generation. 
 
3.4   Colony Forming Unit Assay 
 MSCs were seeded to one 10cm culture dish (1000 cells per dish) per test 
solution and incubated.  Following 10 days of incubation, the dishes were stained with 
Crystal Violet, and circular colonies visible to the naked eye were counted. 
 
  
                                                 
h
 ThermoFisher Scientific, Rochester, NY, USA 
i
 Beckman Coulter, Indianapolis, IN, USA 
j
 Verity Software House, Topsham, ME, USA 
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3.5   Culture Evaluations 
 One flask per test solution was imaged at 24, 72, and 120 hours by phase contrast 
microscopy at 40x total magnification.  When all test solution cultures were imaged, the 
images were randomized, and two evaluators with MSC culture experience graded the 
images for confluency, morphology, and debris in a blinded manner (Table 3).  Due to 
software difficulty, cultures from 5 horses were assessed for 24 hour culture evaluations, 
while cultures from 6 horses were assessed for 72 and 120 hour evaluations. 
 
 
  
Table 3 – Culture Evaluation Parameters 
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3.6   Trilineage Differentiation Assay 
 MSCs expanded with test solutions for 120 hours were subjected to trilineage 
differentiation to assess potency.  For adipogenic differentiation, cells grown in each test 
solution were seeded to 12-well plates (1000 cells/cm
2
)
 
in triplicate wells with BCM.  
After 24 hours, the BCM in each well was replaced with adipogenic induction media 
(Dulbecco’s modified Eagle’s medium F12 with L-glutamine and sodium pyruvatek, 3% 
FBS
l, 10,000 units/mL penicillin, 10mg/mL streptomycin, 25 μg/mL amphotericin Bk, 1 
ng/mL bFGF
m
, 5% rabbit serum
n, 0.033μM/mL biotino, 0.017μM/mL calcium 
pantothenate
o, 0.001μM/mL insulino, 1nM/mL dexamethasoneo, 0.1mg/mL 
isobutylmethylxanthine
o
, and 0.00178mg/mL rosiglithizone
o
)
70
.  After 3 days, media was 
aspirated from each triplicate well and adipogenic maintenance media (adipogenic 
induction media formulation, less isobutylmethylxanthine and rosiglithizone) was added.  
After 3 days, the plates were fixed with 4% paraformaldehyde, stained with Oil Red O
o
, 
and imaged immediately by phase contrast microscopy using a 3-hole template.  
Contamination caused results to be excluded in the PSGAG group for one of the six 
horses. 
 For chondrogenic differentiation, cells grown in each test solution were divided 
into 3 aliquots of 500,000 cells, then centrifuged (300 x g, 4°C, 10 minutes, acc7/dec5) 
to form pellets.  Supernatants were carefully removed from each tube, and 1mL of 
                                                 
k
 Mediatech, Manassas, VA, USA 
l
 HyClone, Inc., Logan, UT, USA 
m
 Corning, Bedford, MA, USA 
n
 Life Technologies, Foster City, CA, USA 
o
 Sigma-Aldrich, St. Louis, MO, USA 
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chondrogenic media was added (Dulbecco’s modified Eagle’s medium 4.5g/dL glucose 
with L-glutamine and sodium pyruvate
k
, 1% FBS
l
, 10,000 units/mL penicillin, 10mg/mL 
streptomycin, 25 μg/mL amphotericin Bk, 0.01μg/mL transforming growth factor β-3o, 
0.1nM/mL dexamethasone
o
, 0.05mg/mL L-ascorbic Acid
o
, 0.04mg/mL proline
o
, and 1% 
ITS Premix
p
)
69
.  The pellets were maintained in culture for 21 days with incubation 
(37°C, humidified air with 5% CO2) and media replacement every 2 – 3 days.  At the 
end of 21 days, media was removed pellets were fixed with 4% PFA (room temperature, 
10 minutes). The pellets were preserved in 70% ethanol until embedding, sectioning, and 
mounting to slides.  Pellet sections were stained with Toluidine Blue
o
, imaged by light 
microscopy at 100x total magnification, and evaluated for cell morphology, distance, 
and ECM staining intensity. 
 For osteogenic differentiation, cells grown in each test solution were plated to 
12-well plates (1000 cells/cm
2
)
 
in triplicate wells.  After 24 hours, BCM in each 
triplicate well was replaced with osteogenic media (Dulbecco’s modified Eagle’s 
medium Ham’s F12 with L-glutamine and sodium pyruvatek, 10% FBSl, 10,000 
units/mL penicillin, 10mg/mL streptomycin, 25 μg/mL amphotericin Bk,1 ng/mL 
bFGF
m, 0.01μM/mL β-Glycerophosphateo, 0.02 nM/mL dexamethasoneo, and 
0.05mg/mL L-ascorbic acid
o
).  The plates were maintained in culture for 21 days with 
incubation and media replacement every 2-3 days.  The plates were fixed with 70% 
ethanol, allowed to dry completely, and stained with 2% Alizarin Red
o
.  The plates were 
allowed to dry completely, then assessed and imaged by phase contrast microscopy. 
                                                 
p
 Discovery Labware, Inc., Bedford, MA, USA 
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3.7   Immunophenotyping Assay 
 MSCs expanded in treated media for 120 hours were analyzed for expression of 
surface markers CD29, CD44, CD45, and MHCII by flow cytometry as previously 
described
69
.  Briefly, MSCs were thawed and stained using antibody dilutions of 1:100 
for CD29
q
, CD44
r
, and MHCII
n
, and 1:33 for CD45
s
 with volumes adjusted for cell 
quantities.  MSCs were combined with staining buffer and primary antibodies (CD29, 
CD44, MHCII) in Eppendorf tubes, incubated (4°C, 45 minutes), pelleted by 
centrifugation (4 x g, 4°C, 5 minutes) and washed twice before resuspension in 500μL 
DPBS.  MSCs were combined with staining buffer and CD45 antibody dilution in 
Eppendorf tubes and incubated (on ice, in the dark, 15 minutes), then centrifuged (2.0 
RPM, 4°C, 3 minutes) and washed twice.  Secondary antibody of 1:100 dilution was 
added to cells, which were then incubated (on ice, in the dark, 15 minutes) and washed 
once before resuspension in 500μL DPBS. 
 Five microliters of 7-amino-actinomycin D
t
 (7-AAD) was added to each sample 
for viability assessment during flow cytometric analysis.  Only live cells were analyzed.  
Samples were analyzed using a FACSCalibur flow cytometer and CellQuest Pro 
acquisition software
u
.  The flow cytometer used a 480nm laser with a 530/30 bandpass 
filter for FITC, 585/45 bandpass filter for PE, and 630 longpass filter for 7-AAD.  The 
                                                 
q
 Beckman Coulter, Indianapolis, IN, USA 
r
 Bio-Rad Laboratories, Redmond, WA, USA 
s
 Monoclonal Antibody Center, Washington State University, Pullman, WA, USA 
t
 BioLegend, San Diego, CA, USA 
u
 Becton, Dickinson, and Company, Franklin Lakes, NJ, USA 
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flow cytometry data was analyzed using FlowJo analysis software
v
.  Surface markers
with greater than 80% detection were considered positive, while markers with less than 
5% detection were considered negative. 
3.8   Prostaglandin E2 Assay 
Culture media supernatants of 4 horses were assayed for prostaglandin E2 (PGE2) 
content using a competitive enzyme-linked immunosorbent assay (ELISA)
w
.
Absorbance was read at 450nm using a Gen5™ microplate reader and analysis 
software
x
.
3.9   Senescence Assay 
MSCs from 1 horse were plated to four 6-well plates (7000 cells/cm
2
) in BCM
(negative control), high-glucose BCM (24mM glucose, positive control), PSGAG test 
solution, or SF test solution, and incubated for either 24, 72, 120, or 240 hours.  At each 
time point, plates were stained using a β-Galactosidase Staining Kity according to the
manufacturer’s instructions, visualized, and imaged by phase contrast and light 
microscopy. 
 
v
 Tree Star, Inc., Ashland, OR, USA 
w
 R&D Systems, Inc., Minneapolis, MN, USA 
x
 BioTek Instruments, Inc., Winooski, VT, USA 
y
 BioVision, Inc., Milpitas, CA, USA 
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GraphPad PRISM
4
 statistical software was used to analyze data.  Distributions
were evaluated by the Shapiro-Wilk distribution test.  Cell count and CFU-F data were 
evaluated by matched repeated measures one-way analysis of variance (RM one-way 
ANOVA) with Dunnett’s multiple comparisons follow-up test.  Culture evaluation data 
were evaluated for normality with the Shapiro-Wilk distribution test, and either RM one-
way ANOVA with Dunnett’s multiple comparisons follow-up test or a Friedman test 
with Dunn’s multiple comparisons follow-up test were applied, depending on the nature 
of the distributions.  A p-value of less than or equal to 0.05 was considered significant. 
Table 4 – Assay plating densities and lengths of expansion. 
3.10   Statistical Analysis
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4. RESULTS 
 
4.1   Growth Kinetics Assay 
 There were no significant differences in percentage of cells in each generation 
after 24 hours of expansion between samples grown in each treated media and the 
control.  After 72 hours of expansion, PSGAG cultures had a significantly greater 
percentage of cells in generation 2 (median, 43%) and a significantly lower percentage 
of cells in generation 4 (1.0%) compared to the control (generation 2, 4.0%, generation 
4, 41%) (Figure 3).  GAGHA cultures had a significantly greater percentage of cells in 
generation 3 (32%) compared to the control (15%).  SF cultures had a significantly 
greater percentage of cells in generations 1 (9.0%) and 2 (40%) compared to controls 
(generation 1, 1.0%, generation 2, 4.0%).  HA cultures did not have significant 
differences from the control in any generation. 
 
  
Figure 3 – Growth Kinetics Data. 
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4.2   Cell Counts 
 One of the six horses was an outlier and excluded from cell count analysis, 
though this did not change the results of the statistical tests.  There were no significant 
differences between test solutions and the control at 24 hours (Figure 4).  At 72 hours, 
PSGAG (range, 420,000 – 650,000, mean, 435,000), GAGHA (380,000 – 1,050,000, 
556,667), and SF (300,000 – 1,200,000, 508,333) cultures were significantly decreased 
from the control (800,000 – 2,000,000, 1,268,333) (Figure 4).  HA (680,000 – 
1,700,000, 1,056,667) cultures were not significantly different from the control at 72 
hours. 
 
  
Figure 4 – Cell Count Data (mean, 95% confidence interval). 
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4.3   Colony Forming Unit Assay 
GAGHA (range, 158 - 377, mean 265) and SF (64 – 429, 190) colony counts were 
significantly decreased, and HA (251 – 652, 414) colony counts were significantly 
increased from the control (253 – 533, 363) (Figure 5).  No colonies were observed on 
PSGAG test solution plates, though single cells with flattened and circular morphology 
were visualized and took up Crystal Violet stain (data not shown; Figure 5B).  Small 
colonies observed in SF cultures had unique morphology.  As opposed to the circular, 
evenly distributed colonies observed in control plates (Figure 5C), colonies growing in 
SF supplemented cultures were tightly packed with defined edges (Figure 5D). 
 
Figure 5 - Colony Forming Units Data. (A) Colony Forming Units 
–Fibroblastic (mean, 95% confidence interval), (B) representative 
MSC grown in PSGAG test solution for 10 days, then stained with 
Crystal Violet, 200x total magnification, (C) colony from BMC 
group, 40x (D) colony from SF group, 40x). 
B 
C D 
A 
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4.4   Culture Evaluations  
 No significant differences were found among test solution groups at 24, 72, or 
120 hours for debris in culture.  SF cultures were significantly less confluent than 
controls at 72 and 120 hours, while PSGAG cultures were significantly less confluent 
than controls at 120 hours (Figure 6).  Morphology of these cultures also received worse 
scores than controls at 72 hours.  All other treatments were not significantly different 
Figure 6 – Culture Evaluation Data (median; 24 hour SF data, n = 
5). 
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from controls at any time point for any parameter, however, HA and GAGHA cultures 
appeared to have greater confluency than controls at 72 and 120 hours. 
 
 
  
Table 5 – Culture evaluation scores (median; for 24 hour SF scores, n = 
5).  See Table 3 for parameter descriptions, page 21. 
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4.5   Trilineage Differentiation Assay 
 MSCs from all test solution groups successfully underwent trilineage 
differentiation into adipocytes, chondrocytes, and osteoblasts (Table 6, Figure 7).  
Although not statistically significant, MSCs expanded in PSGAG supplemented BCM 
appeared to accumulate less ECM in chondrogenic differentiation as indicated by the 
distance between cells parameter (Figure 7C). 
 
 
 
 
 
 
 
 
 
 
 
  
Table 6 – Trilineage Differentiation Results 
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4.6   Immunophenotyping Assay 
 MSCs maintained in culture with treated media for 120 hours showed expected 
surface marker phenotype of CD29
+
, CD45
-
, and MHCII
-
.  Though not significantly 
different from controls, expression of CD44 appeared to be decreased across test 
solution groups, with the lowest expression in the PSGAG test solution group (Table 7).  
Expression of less than 5% was considered negative, while expression of greater than 
80% was considered positive. 
 
  
Table 7 – Immunophenotyping results of cells expanded in treated media 
for 120 hours, reported in percentages.  A positive (+) distinction required 
greater than 80% expression, while a negative (-) distinction required less 
than 5.0% expression for all horses (n = 6).  CD44 expression was 
heterogeneous (median).   
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4.7   Prostaglandin E2 Assay 
 Test solution means were not significantly different from the control, however, 
the range of concentrations for GAGHA culture supernatants (1014.18 – 5779.82 
pg/mL) appeared greater than that of the control (0.00 – 1495.44 pg/mL), while the 
ranges of PSGAG culture supernatants (0.00 – 254.81 pg/mL) and SF culture 
supernatants (0.00 – 314.14 pg/mL) appeared narrow compared to the control (Figure 8).  
HA culture supernatants had a moderate range (0.00 – 2878.05 pg/mL).  PGE2 
concentrations appeared to be horse-dependent. 
  
Figure 8 – PGE2 Concentrations in Media Supernatants 
(mean, range; Horse 1, blue; Horse 2, pink; Horse 3, 
green; Horse 4, orange). 
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4.8   Senescence Assay 
 Senescence was not detected in control and test solution wells at 24, 72, and 120 
hours (n = 1).  After 240 hours, positive senescence staining was observed in wells 
containing MSCs incubated with positive and negative control media and BCM 
supplemented with SF test solution.  Osteogenic differentiation was also observed in SF 
wells, confirmed by Alizarin Red S staining (Figure 7).  PSGAG treated MSCs were 
negative for β-Galactosidase staining. 
 
 
 
 
 
 
  
Figure 9 – β-Galactosidase Staining (phase contrast (A-C) and light (D-F) 
microscopy of MSCs incubated for 240 hours in positive control media (A, D), 
PSGAG test solution (B, E), and SF test solution (C, F)). 
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5. DISCUSSION AND CONCLUSIONS 
 
 Coupling regenerative medicine with common intra-articular DMOADs may be a 
valuable therapy for equine joint disease, however, effects of the common DMOADs 
PSGAG and GAGHA on MSCs were previously unknown.  PSGAG, GAGHA, and 
allogenic SF had negative effects on MSC viability, proliferation, and possibly function.  
The current study demonstrated no detrimental effects of HA on MSC proliferation, and 
possibly beneficial effects of HA on MSC viability.  These findings indicate that the 
exposure of MSCs to PSGAG or GAGHA is detrimental to MSCs and that endogenous 
SF may hinder MSC survival or induce differentiation, while HA had no adverse effects 
on MSC viability or proliferation. 
 Our findings are in agreement with those of Bohannon et al. regarding the effects 
of HA on MSC viability and proliferation, in that HA had no adverse effects on MSC 
proliferation in vitro
71
.   The growth kinetics assay indicated no difference in the lag and 
log phases of growth between HA and control cultures
72
.  Confluency scores of HA 
cultures suggest a possible positive effect of HA on MSC proliferation.  Additionally, 
results of the CFU-F experiment indicate a beneficial effect on MSC viability when 
plated in low densities.  Characterization of MSCs was not altered after 120 hours of 
expansion to HA, with the exception of CD44 expression, which was decreased in all 
test solution groups.  Our findings of similar PGE2 production between HA and control 
cultures are also in agreement with those of the Bohannon study
71
.  This suggests that 
the modulatory functions of MSCs are not hindered after expansion with HA.  
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Additional investigation of modulator production by MSCs after expansion with HA is 
warranted.   
 In contrast, PSGAG cultures performed poorly in all assays.  The most 
conspicuous effects were the change in morphology from spindle-shaped to round and 
flattened, the delayed recovery after plating demonstrated by confluency scores at 120 
hours, and the complete lack of colonies in the CFU-F assay.  These observations may 
be attributed to cell death rather than differentiation or senescence, as the cells lacked 
morphology and vacuoles indicating adipogenic differentiation or the deposition of ECM 
characteristic of chondrogenic or osteogenic differentiation, and were negative for 
senescence after 10 days of culture (n = 1).  Decreased proliferation in the presence of 
PSGAG is consistent with the findings of Glade et al. who found decreased cellular 
proliferation in chondrocyte cultures
25
.  Our finding suggest a similar inhibition of 
proliferation when MSCs are exposed to PSGAG.  Concentrations of PGE2 appeared 
decreased in PSGAG and SF treated media supernatants, though differences were not 
statistically significant.  The possibly decreased mediator production in MSCs expanded 
with these test solutions supports our hypothesis of cell death in PSGAG cultures and 
osteogenic differentiation in SF cultures, however, additional study is warranted.  The 
detrimental effects of PSGAG on MSC viability could be density dependent, as the 
CFU-F plates were plated at 18 cells/cm
2 
and showed the most dramatic effect with 
failure to form colonies.  It is possible that higher densities allowed MSCs to acclimate 
or somewhat recover from the effects of PSGAG in the trilineage differentiation and 
immunophenotyping assays, which used cells plated at 10,000 cells/cm
2
 for expansion.  
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Though the immunophenotypic profile of CD29
+
, CD45
-
, and MHCII
-
 was retained in 
PSGAG and SF cultures, PSGAG cultures appeared to have reduced expression of CD44 
compared to controls and other test solution cultures.  MSCs have previously 
demonstrated a range of expression for CD29, positive expression of CD44 (> 70%), and 
robustly negative expression of MHCII (< 5.0%)
73
.  Possibly decreased expression of 
CD44 in PSGAG cultures could result in decreased adhesion and proliferation
74
.  
Additional investigation with a greater sample size is warranted.   
 MSCs have demonstrated a fluctuating expression of MHCII and other surface 
proteins when primed by exposure to cytokines and chemokines in an inflamed 
environment, including those present in synovial fluid of a diseased joint
39,58
.  A 
significant increase in MHCII expression was not elicited by exposure to any conditions 
in the current study, including SF.  However, SF cultures demonstrated greater reduction 
in proliferation than PSGAG cultures.  This is in contrast to the results of the pilot study, 
which suggested a possible increase in proliferation.  This discrepancy could be due to 
the difference in synovial fluid used for each experiment.  For the pilot study, pooled 
synovial fluid was used, while in the current study, synovial fluid from nly two horses 
was used.  Individual differences from the two synovial fluid donor horses could be the 
reason for the discrepancy between our two studies.  Nevertheless, replacement of 
endogenous SF with HA before MSC administration could be beneficial to the survival 
of MSC once injected into the joint, and may delay priming MSCs, decreasing the risk of 
an immune response after injection
39
.    
 40 
 
 All test solution groups retained the ability to differentiate into adipocytes, 
chondrocytes, and osteoblasts after 120 hours of expansion with test solutions.  
Chondrogenesis of canine bone marrow-derived MSCs in the presence of PSGAG has 
been evaluated previously in alginate and micromass cultures
75
.  In micromass cultures 
with PSGAG, chondrogenesis was inhibited, as decreased proteoglycan production was 
observed by Alcian blue staining
75
.  Results of the current study suggest a possible 
reduction in chondrogenic ability after MSC expansion with PSGAG as well.  Though 
chondrogenic differentiation was successful, MSCs cultured with PSGAG appeared to 
produce less ECM compared to other treatments, according to the scoring of distance 
between cells.  This possibility is in agreement with results from the previous study
75
.   
 Limitations of the current study include a low sample size (n = 6), testing few 
cellular densities, and only testing one concentration per test solution.  Multiple cell 
densities for intra-articular injection have been studied in the horse and other species 
such as humans and rabbits, the most popular doses ranging from 10
6
 to 10
8
 cells
44,76
.  
Therefore, expanding MSCs at additional densities would have provided more 
information on the apparent density-dependent effects of HA and PSGAG on MSC 
viability.  Further, intra-articular dosing varies with joint size, so testing a clinically 
relevant range of concentrations for each test solution would have also provided more 
comprehensive information.  Additionally, testing for the presence of other 
inflammatory mediators such as interleukin-10 (IL-10) or IL-6 would provide more 
information on immunomodulatory functions of MSCs following expansion with these 
medications. 
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 Results of the current study reveal that MSC expansion with PSGAG or SF will 
hinder viability and proliferation, while expansion with HA may increase viability 
without hindering proliferation in vitro.  Therefore, combination of MSCs with PSGAG 
and SF may inhibit viability and function of implanted MSCs, while combination of 
MSCs with HA may supplement proliferation and immunomodulatory function of MSCs 
in culture and after intra-articular implantation while providing the anti-inflammatory 
and disease modifying effects demonstrated by HA in other studies
14
.  In vivo studies are 
warranted to investigate these possibilities. 
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APPENDIX A 
 
 
 
 
 
 
  
Colony Forming Unit 10 cm Plates, Horses 1 – 3  
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Colony Forming Unit 10 cm Plates, Horses 4 – 6   
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Representative Colony Forming Unit Microscopic Images 
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APPENDIX B 
 
  
24 Hour Culture Evaluation Images, 40x, Horses 1 – 3  
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24 Hour Culture Evaluation Images, 40x, Horses 4 – 6  
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72 Hour Culture Evaluation Images, 40x, Horses 1 - 3  
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72 Hour Culture Evaluation Images, 40x, Horses 4 – 6   
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120 Hour Culture Evaluation Images, 40x, Horses 1 – 3   
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120 Hour Culture Evaluation Images, 40x, Horses 4 – 6   
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Representative Adipogenesis Images, Horse 1 
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Representative Adipogenesis Images, Horse 2 
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Representative Adipogenesis Images, Horse 3 
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Representative Adipogenesis Images, Horse 4 
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Representative Adipogenesis Images, Horse 5 
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Representative Adipogenesis Images, Horse 6 
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Representative Chondrogenesis Images, Horses 1 - 3 
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Representative Chondrogenesis Images, Horses 4 – 6 
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Representative Osteogenesis Images, Horse 1 
 73 
 
 
  
Representative Osteogenesis Images, Horse 2 
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Representative Osteogenesis Images, Horse 3 
Note: SF and BCM control images saved incorrectly. 
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Representative Osteogenesis Images, Horse 4 
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Representative Osteogenesis Images, Horse 5 
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Representative Osteogenesis Images, Horse 6 
